Premium
AM‐10: Alzheimer's disease: Aβ‐amyloid as the principal molecular therapeutic and diagnostic target
Author(s) -
Masters Colin
Publication year - 2007
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2007.04.292
Subject(s) - neurodegeneration , amyloid precursor protein , chemistry , alzheimer's disease , amyloid (mycology) , neuroscience , glutamatergic , p3 peptide , extracellular , mechanism (biology) , microbiology and biotechnology , biochemistry , biology , disease , medicine , receptor , glutamate receptor , inorganic chemistry , philosophy , epistemology
synaptic dysfunction and cytoskeletal pathology. Indeed, data emerging from studies of mouse models of AD support a key role for neurohormesis mechanisms in protecting the brain against AD. Certain dietary phytochemicals may also protect neurons against AD by hormesis-based mechanism. A better understanding of the molecular mechanisms of neurohormesis, may lead to the optimization of current preventative strategies for AD, and to the developmental of novel interventions as well.